Section 174 Research and Experimental Expenditure Capitalization Requirements

Section 174 has moved through three distinct regimes since 1954, and the compliance obligations of each one still matter today, even for the periods that have technically closed. Understanding how the rule treated research costs before 2022, what changed during the mandatory capitalization years of 2022 through 2024, and what the One Big Beautiful Bill Act established afterward is the only way to know which obligations a business has already discharged and which ones remain open.

How Section 174 treated research costs before 2022

Section 174, enacted in 1954, gave businesses a choice that lasted nearly seven decades: deduct research and experimental costs in full in the year paid or incurred, or elect to capitalize and amortize them over at least 60 months.

Software development had not yet been written into the statute as a named category, which left some ambiguity about how development costs should be classified. For R&D-intensive businesses, the practical effect of the pre-2022 regime was simple: engineering payroll, contractor payments, and supplies consumed during development reduced taxable income dollar-for-dollar in the year incurred. The Tax Cuts and Jobs Act of 2017 took that simplicity away.

What the TCJA Changed

The Tax Cuts and Jobs Act of 2017 eliminated the expensing choice. But the law delayed its own effective date to tax years beginning after December 31, 2021, building a four-year gap between the moment Congress passed the change and the moment it actually hit a tax return.

That gap did more damage than a shorter runway would have. The TCJA also wrote software development directly into the statute as a research and experimental expenditure, which meant nearly every SaaS company and any business building proprietary software became a Section 174 taxpayer, regardless of whether it ever pursued the separate R&D credit under Section 41. A 2024 legislative effort to restore domestic expensing retroactively failed to advance, leaving mandatory capitalization in place through tax year 2024 for most taxpayers.

What Qualified as R&E Under the 2022–2024 Rules

Section 174 casts a far wider net than the Section 41 R&D credit, and that breadth is what caught so many businesses off guard.

The real test for whether a cost falls under Section 174 is uncertainty. Once that uncertainty resolves and production begins, those costs step outside Section 174 and become ordinary business expenses. Costs that never qualify include quality control testing of finished products, efficiency surveys, management studies, consumer research, and advertising, along with land or depreciable property used in research (though the depreciation on that property can itself count as R&E).

Set against this, the Section 41 credit is narrower on several fronts. Activities must pass a four-part test covering permitted purpose, technological nature, uncertainty, and process of experimentation. One might argue this mismatch is a technicality, but its consequences are concrete: a business could carry significant Section 174 capitalization obligations while generating little or no Section 41 credit value, particularly if it relied heavily on contractors or offshore developers. That gap between the two sections' scope resurfaces later when the Section 280C interaction comes into play.

The compliance burden the 2022–2024 period created and still leaves behind

The phrase "the OBBBA fixed it" undersells what actually happened. For businesses that capitalized domestic R&E costs in 2022, 2023, or 2024, nothing about recovering those balances happens on its own. The unamortized amounts require affirmative decisions about recovery method, and those decisions carry downstream consequences for tax provisions, owner-level returns, and state filings.

The mid-year convention that applied during those years meant year one delivered only half a year of amortization, so a company that capitalized two full years of R&E before fully grasping the rule could be carrying a substantial unamortized balance into 2025 and beyond. Revenue Procedure 2026-32 gives you a path to implement Section 174A, recover those 2022-2024 balances, and correct research expenditure methods under automatic consent procedures through 2026 and 2027. The waiver of the prior-five-year change rule runs through tax years beginning before January 1, 2028, but the Section 174A automatic change itself only covers tax years beginning before January 1, 2026.

The OBBBA opened two transition paths for the remaining unamortized balances: accelerate everything into 2025 in a single year, or spread the recovery ratably over 2025 and 2026. Eligible small businesses, defined by the gross receipts threshold under Section 448(c), had a third option: they could apply Section 174A retroactively by amending 2022–2024 returns under Rev. Proc. 2025-28, with a deadline of the earlier of July 6, 2026 or the applicable Section 6511 refund-claim deadline. That window has closed, and businesses that missed it should not treat retroactive filing as something still available to them.

The correct recovery vehicle depends on the taxpayer and the year: Form 3115, a statement in lieu of Form 3115, a Section 481 adjustment, amended returns, or partnership administrative adjustment requests, each with its own procedural demands. AAON, Inc. illustrates how even large, sophisticated companies face this as an active choice rather than a passive default: the company elected to deduct all 2025 qualifying domestic R&D expenses as incurred and separately elected to accelerate all remaining unamortized domestic R&D expenses from 2022 through 2024 fully into tax year 2025. CPS Technologies Corp shows the recovery can stretch across multiple reporting periods, having expensed portions of its unamortized Section 174 R&E amounts in 2025 and the first quarter of 2026, with additional quarterly amounts expected through the end of 2026.

What Section 174A Establishes for Domestic R&E Going Forward

Section 174A permanently restores immediate expensing for domestic research and experimental expenditures for tax years beginning after December 31, 2024. But calling it a simple reversion to pre-2022 law misses what the statute actually does: it introduces a new structure with its own elections and a bifurcated treatment of domestic versus foreign research that did not exist before the TCJA.

Under the default rule, any taxpayer incurring domestic R&E expenditures in a tax year beginning after December 31, 2024 may deduct them in full in the year paid or incurred, regardless of company size. "Domestic" means research activities performed within the United States, the District of Columbia, or Puerto Rico, specifically any R&E expenditure not attributable to foreign research as defined in Section 41(d)(4)(F). Section 174A is a permanent provision, not a temporary patch subject to expiration, a meaningful distinction from the uncertainty that surrounded the failed 2024 legislative attempt.

Two optional alternatives exist for taxpayers who find that capitalizing domestic R&E serves them better than expensing it. A 60-month amortization election lets a taxpayer capitalize and amortize domestic R&E starting from the month it first realizes benefits from the research. A 10-year ratability election, under conforming amendments to Section 59(e), allows deduction ratably over 10 years beginning with the tax year the expenditures were made. Section 174 itself was amended so it now applies only to foreign R&E, which remains on a 15-year amortization schedule, making the current statutory structure a two-code-section regime: Section 174A for domestic costs, Section 174 for foreign ones. Impinj, Inc. shows how the new regime and the old balances sit side by side on the same books: the company began deducting domestic Section 174 costs in 2025 following the OBBBA's enactment, while still carrying a deferred tax asset tied to previously capitalized Section 174 expenditures as of December 31, 2025.

Foreign R&E Capitalization as the Dominant Ongoing Compliance Obligation

For any business with offshore R&D activity, whether through foreign development contractors, offshore engineering teams, or research conducted through foreign subsidiaries, the post-OBBBA landscape is not simply "expensing restored."

Foreign R&E expenditures remain subject to 15-year amortization under amended Section 174, with no change from the TCJA rules. The OBBBA's relief applies only to domestic research. Classification has to rest on where the research activity is actually performed, not on the account name used in the books and not on the nationality of the contracting entity. A domestically incorporated contractor doing development work abroad produces foreign R&E costs just the same. Cross-border cost-sharing arrangements, transfer pricing, foreign subsidiaries, branches, and IP ownership structures can each require separately scoped international-tax review to determine which entity bears the R&E expenditure and where it counts as incurred. The incentive built into this structure is plain: immediate domestic expensing against 15-year foreign amortization pushes businesses toward siting research onshore, and that asymmetry belongs in any decision about where to locate R&D operations.

The Section 280C Interaction and the Voluntary Capitalization Election

Businesses claiming both the Section 41 R&D credit and the Section 174A deduction now face a coordination requirement introduced by the OBBBA's changes to Section 280C, and skipping that coordination can quietly erode the value of one benefit or the other. Under amended Section 280C(c), you must reduce domestic R&E expenditures deductible under Section 174A by the amount of the research credit you claim under Section 41, unless you elect instead to reduce the credit. The design prevents the same dollar of spending from generating both a full deduction and a full credit. If a taxpayer capitalizes rather than deducts research expenditures and the research credit exceeds the amount allowable as a deduction, the capital account for those expenses must be reduced by the excess, so the 280C interaction follows the taxpayer even into voluntary capitalization.

The Section 163(j) interaction is what makes voluntary capitalization worth considering: taxpayers that capitalize and amortize domestic R&E costs over 60 months maintain a higher adjusted taxable income, which raises the ceiling for deductible business interest expense, a real difference for leveraged businesses, closely held companies carrying significant debt, or mortgage banking entities. The Section 59(e) 10-year ratable election offers a third path, and it matters most for alternative minimum tax planning, but the corporate alternative minimum tax and the base erosion and anti-abuse tax interact with Section 174 treatment in ways that call for entity-specific analysis, especially when a larger corporate group has international affiliates. Immediate expensing remains the right default for most businesses in most years, but treating it as automatic, without modeling the 163(j) and 280C interactions, is a planning gap.

Industry-specific compliance obligations that Section 174 creates beyond the basic tax return

Section 174's reach extends well past the federal return, into audit opinions, income tax provisions, and regulatory cost reports, and that reach looks different depending on the industry.

Financial statement audits conducted under ASC 740 have to account for all three phases of Section 174 history at once.

SOC 1 and SOC 2 service organizations carry a particular exposure here. Technology-intensive service organizations subject to SOC examinations are disproportionately affected by Section 174, since software development counts as R&E by statute, making nearly every SaaS company a Section 174 taxpayer whether or not it pursues the R&D credit at all. Proc. 2025-28 and Rev. Proc. 2026-32.

HUD 232 borrowers and skilled nursing operators face a version of this same obligation. If operators of HUD-insured multifamily properties and skilled nursing facilities invest in proprietary care-management software, electronic health record platforms, or process-improvement technology, they generate qualifying R&E expenditures under Section 174A, and the immediate expensing now available can give them real cash-flow relief. For HUD 232 borrowers subject to annual audited financial statements, the reclassification of previously capitalized R&E into current deductions, and the corresponding reversal of deferred tax liabilities, must be disclosed clearly and reconciled against regulatory cost reports. If skilled nursing operators sit inside larger health systems with international affiliates, they also need to evaluate CAMT, Section 163(j), and foreign tax credit interactions tied to their Section 174 method choice.

Mortgage banking carries a comparable obligation. Mortgage servicers and originators that invest in loan origination systems, compliance automation, and underwriting technology have software development costs that qualify as R&E under Section 174, putting method choices squarely in front of mortgage banking auditors and compliance teams. Those auditors need to verify that 2022–2024 capitalized software balances are being recovered properly under the chosen transition method, that state conformity has been assessed, and that the Section 163(j) interaction with any voluntary capitalization election has been modeled, particularly given the leverage levels common across mortgage banking entities.

State tax conformity as an underappreciated compliance gap in the post-OBBBA landscape

Federal conformity does not guarantee state conformity, and for multi-state businesses, the state-level treatment of both the 2022–2024 legacy balances and the post-2024 domestic expensing regime is still an open question. States differ in whether they follow IRC Section 174 as amended, whether they let taxpayers elect into particular versions of the rule, and whether they have acted to conform to Section 174A. Some states may still adjust these positions through special legislative sessions tied to the 2025 filing season.

A business that correctly expenses all domestic R&E on its federal return under Section 174A can still face capitalization requirements in one or more states, which creates a book-to-state reconciliation that has to be tracked separately from the federal provision. Financial statement auditors must consider state deferred tax effects when they evaluate income tax provisions under ASC 740, so state conformity uncertainty becomes an audit-relevant variable, and it can affect the size and recoverability of deferred tax assets on the balance sheet. Each state in which a business files should be evaluated individually for its current Section 174 or Section 174A conformity position before the federal method change is finalized.

What Businesses Must Do Now

If you treat Section 174 as a once-a-year filing task, you miss elections, mishandle transition balances, and leave real planning opportunities on the table. The three-phase history this piece has traced calls for a structured, multi-year response instead.

Phase 1 cleanup covers the 2022–2024 balances, and you start by identifying all domestic R&E costs capitalized during those years and determining how much remains unamortized. From there, businesses need to choose among the available transition methods, one-year acceleration into 2025, two-year ratable recovery over 2025–2026, or continued five-year amortization, and document that election consistently across every entity in a controlled group or pass-through chain. Anyone who filed the small-business retroactive election under Rev. Proc. The appropriate Form 3115, statement in lieu of Form 3115, or accounting method change documentation required under Rev. Proc. 2026-32 still needs to be filed, with automatic consent procedures available through tax years beginning before January 1, 2028.

Phase 2 covers current-year compliance for 2025 and 2026 domestic R&E. It also means evaluating whether the default immediate expensing under Section 174A is actually the right call, or whether voluntary 60-month capitalization or 10-year ratable expensing serves the entity better given its leverage, loss position, expiring carryforwards, or interest deductibility ceiling under Section 163(j). The Section 174A method needs to be coordinated with any Section 41 R&D credit claim and the Section 280C election, modeling both the reduced-deduction and reduced-credit paths before Form 6765 is filed.

Beyond those two phases, the advisory work does not stop. You should assess state conformity in every filing state before you finalize the federal method, not assume it. SOC service organizations, HUD 232 borrowers, skilled nursing operators, and mortgage banking entities each need their Section 174 method change reflected in tax controls and, where relevant, in regulatory cost report disclosures. And as R&D operations expand or contract offshore, the tax cost of foreign R&E, 15-year amortization with no credit eligibility, belongs in site and staffing decisions as they're being made, not as something discovered after the fact at filing time.

A rule with three distinct phases, several elections, cross-provision interactions with Sections 41, 163(j), and 280C, and a state conformity landscape that varies by jurisdiction is not something a business resolves once and sets aside, and it rewards proactive, year-round advisory engagement, because the cost of treating it as a once-a-year checkbox appears years later, in unamortized balances nobody tracked and elections nobody made in time.